XML 59 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (USD $)
Dec. 31, 2012
Dec. 31, 2011
Current assets:    
Cash and cash equivalents $ 5,646,021 $ 17,350,116
Short-term investments 8,034,001 12,863,420
Accounts receivable 830,433 467,909
Accounts receivable from affiliated entity 36,234 38,406
Prepaid expenses and other current assets 471,328 746,049
Prepaid expenses and other current assets from affiliated entity 887,167 441,186
Deferred tax asset 62,728 0
Total current assets 15,967,912 31,907,086
Restricted cash 100,410 100,059
Fixed assets, net 363,021 295,785
Investment in affiliated entity 10,703,332 9,071,513
Intangible assets, net 7,489,315 9,310,485
Goodwill 10,113,371 [1] 10,113,371 [1]
Common stock warrants 267,200 100,000
Other assets 134,193 208,262
Total assets 45,138,754 61,106,561
Current liabilities:    
Accounts payable and accrued expenses 3,181,574 4,318,942
Accounts payable and accrued expenses due to affiliated entity 187,275 20,344
Accrued clinical trial expenses 1,405,896 1,059,372
Common stock warrants 2,859,899 5,176,319
Deferred revenue 353,391 79,502
Deferred revenue from affiliated entity 388,542 388,542
Total current liabilities 8,376,577 11,043,021
Deferred revenue, net of current portion 88,609 80,450
Deferred revenue from affiliated entity, net of current portion 1,586,694 1,961,694
Deferred rent 65,076 80,875
Deferred tax liabilities 164,393 78,859
Total liabilities 10,281,349 13,244,899
Commitments and contingencies      
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding: 26 and 26 at December 31, 2012 and December 31, 2011, respectively 0 0
Common stock—par value $0.001; Authorized shares: 300,000,000, issued and outstanding: 144,313,005 at December 31, 2012 and 134,968,394 at December 31, 2011 144,313 134,968
Additional paid-in capital 263,897,116 257,235,707
Accumulated deficit (229,760,129) (210,091,174)
Accumulated other comprehensive income 73,362 35,393
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 34,354,662 47,314,894
Non-controlling interest 502,743 546,768
Total stockholders' equity 34,857,405 47,861,662
Total liabilities and stockholders’ equity $ 45,138,754 $ 61,106,561
[1] Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.